CD274 and neoplasm: The latest results at the 2022 San Antonio Breast Cancer Symposium indicate that this triple combination therapy has promising anti-tumor activity (ORR 55.3% and DCR 84.2%) and manageable toxicity regardless of PD-L1 status [57].